May 23, 2026

Recruitment Performance and Patient Access It is 3:00 AM in New Jersey, and a Global Clinical Operations Lead is staring at a recruitment dashboard that has turned red. A Phase III trial is stalled. The feasibility reports from three months ago promised twenty patients per month from a premier institute in Delhi. The reality? Zero. The Ethics Committee (EC) meeting was postponed twice. The Principal Investigator (PI) delegated responsibilities to a junior resident. However, the resident does not fully understand the protocol. In addition, the site has not yet ordered the centrifugation equipment required for primary endpoint samples. This is the reality of clinical trial execution in India. It often occurs when site selection is based on prestige rather than operational readiness. As a result, delays, compliance issues, and operational gaps become more common. Sponsors often enter the Indian market because of the large patient pool and lower operational costs. However, they frequently underestimate the complexities of the New Drugs and Clinical Trials Rules (NDCT), 2019. In addition, many overlook the ground-level execution risks involved in trial operations. As a result, operational delays and compliance challenges become more likely. Identifying a high-performing site is not about choosing the biggest hospital. Instead, it is about selecting a site that balances regulatory hygiene with consistent recruitment performance. In addition, the site must maintain high-quality ALCOA+ data integrity standards. As a result, sponsors can achieve more reliable and compliant trial execution. Executive Summary: The Financial Impact of Site SelectionFor a sponsor, a site is an investment. In India, the gap between a high-performing site and a struggling one is often measured in months of delay and thousands of dollars in rescue costs. For example, a site that delays its EC submission by three weeks can postpone the country’s entire First Patient In (FPI). As a result, multiple global milestones may also be delayed. • High-performing sites in India provide faster recruitment cycles. In many cases, patient enrollment is twice as fast as in Western sites. • Additionally, these sites maintain predictable regulatory timelines through CDSCO (Central Drugs Standard Control Organisation). • Well-managed longitudinal studies also achieve retention rates above 90% in many cases. • Another major advantage is the generation of clean data that passes FDA and EMA inspections successfully. • On the other hand, poor site selection can create serious operational and regulatory challenges. • For instance, sponsors may face regulatory queries and potential Form 483 observations under US FDA oversight. • Sponsors may also need to over-recruit globally to compensate for sites that over-promised and under-delivered. • Consequently, overall study timelines and budgets can be significantly affected. The Indian Regulatory Landscape: Beyond the BasicsTo find a top site, you must understand the infrastructure they operate within. The regulatory framework in India is governed by the DCGI (Drug Controller General of India) under the CDSCO. Since the 2019 NDCT rules, the process has become more streamlined but also more stringent regarding ethics and compensation.High-performing sites demonstrate an intimate knowledge of:• CTRI (Clinical Trials Registry-India): Ensuring registration is done accurately before the first patient is enrolled.• Ethics Committee Registration: Only ECs registered with the CDSCO can oversee clinical trials. A site using an unregistered or lapsed EC is a non-starter.• SAE Reporting: The 24-hour reporting window to the DCGI and EC is non-negotiable. Top sites have internal systems to ensure this timeline is never missed.• Compensation Rules: Understanding the formula-based compensation for trial-related injuries is critical for risk management. Where the Delays Actually HappenMost feasibility assessments focus on “Patient Potential.” This is a mistake. In India, the bottleneck is rarely the number of patients in the waiting room; it is the process of moving those patients through the screening funnel. Real Operational Insights: What Works vs. What FailsThrough years of monitoring and managing sites across the subcontinent, I have seen a clear pattern. The “star” investigators at Tier 1 private hospitals are often spread too thin. They are consultants, researchers, and frequent speakers at international conferences. They have the patients, but they do not have the time.A high-performing site usually features a “Rising Star” investigator—someone who is building their reputation, who remains accessible for site initiation visits (SIV), and who personally oversees the Study Coordinators (SCs).Evidence of a high-performing site includes:• Dedicated Clinical Research Coordinators (CRCs): Not just part-time staff shared between three different departments.• Archival Systems: Well-organized, fire-safe, and moisture-controlled areas for long-term storage of Source Documents.• Patient Centricity: Does the site have a plan for patient travel reimbursement? In India, logistics are a major cause of dropout. Effective site management accounts for these small but vital details. Case Studies: Real-World Execution ScenariosCase Study 1: The Oncology Recruitment Illusion• Study Type: Phase II Lung Cancer (Late Stage).• Site Type: Large Government Specialty Hospital.• Problem: The site predicted 30 patients in 6 months but enrolled only 2 after 4 months.• Root Cause: The PI was overwhelmed with general OPD (Outpatient Department) patients and had no dedicated space for trial-specific informed consent discussions. Long wait times led potential subjects to choose standard-of-care elsewhere.• Action Taken: Moved the study to a private specialty center with similar patient volume but a dedicated trial wing and appointed a second Sub-Investigator.• Outcome: Enrollment targets met; data quality improved.• Lesson Learned: Volume does not equal enrollment capacity. Look for infrastructure that supports the patient experience. Case Study 2: The Vaccine Data Integrity Crisis• Study Type: Phase III Multi-center Vaccine Trial.• Site Type: Private Medical College.• Problem: During an interim audit, the CRA found discrepancies in temperature logs for the Investigational Product (IP).• Root Cause: The site used a common pharmacy fridge with no back-up power source (common in certain Indian states with power fluctuations).• Action Taken: Immediate installation of a medical-grade refrigerator with 24/7 digital temperature monitoring and a dedicated UPS (Uninterruptible Power Supply).• Outcome: Prevented the loss of all IP; sites now require pre-qualification of storage equipment.• Lesson Learned: Never assume a hospital-grade fridge is sufficient for clinical trial IP. Case Study 3: The Rare Disease Startup